Skip to main content

Adjunctive brexpiprazole for the treatment of major depressive disorder.

Publication ,  Journal Article
Beyer, JL; Weisler, RH
Published in: Expert Opin Pharmacother
December 2016

The lifetime prevalence of major depressive episodes in the United States is nearly 17%. Clinical trials and clinical effectiveness studies have demonstrated that many patients will fail to achieve remission using traditional monotherapy, contributing to significant morbidity and suffering. Because of this, augmentation strategies have been proposed to improve both treatment response and remission. Areas covered: Brexpiprazole is a second generation antipsychotic (SGA) approved by the US FDA in 2015 as an add-on treatment to an antidepressant medication for the treatment of adults with MDD, based on the results of two large-scale, randomized, placebo-controlled trials. It is thought to exert its antidepressant effect by a partial agonism of both the dopamine D2 and serotonin 5HT1A receptors. In addition, it also has potent antagonistic activity at 5HT2A, α1B and α2 C receptors, which may also contribute to monoamine transmission regulation. Expert Opinion: Overall, the tolerability of brexpiprazole is promising with relatively low rates of side effects and discontinuation rates, thus establishing it as a new option for the treatment of depression.

Duke Scholars

Published In

Expert Opin Pharmacother

DOI

EISSN

1744-7666

Publication Date

December 2016

Volume

17

Issue

17

Start / End Page

2331 / 2339

Location

England

Related Subject Headings

  • Treatment Outcome
  • Thiophenes
  • Serotonin 5-HT1 Receptor Agonists
  • Receptors, Serotonin, 5-HT1
  • Receptors, Dopamine D2
  • Randomized Controlled Trials as Topic
  • Quinolones
  • Pharmacology & Pharmacy
  • Humans
  • Dopamine
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Beyer, J. L., & Weisler, R. H. (2016). Adjunctive brexpiprazole for the treatment of major depressive disorder. Expert Opin Pharmacother, 17(17), 2331–2339. https://doi.org/10.1080/14656566.2016.1254188
Beyer, John L., and Richard H. Weisler. “Adjunctive brexpiprazole for the treatment of major depressive disorder.Expert Opin Pharmacother 17, no. 17 (December 2016): 2331–39. https://doi.org/10.1080/14656566.2016.1254188.
Beyer JL, Weisler RH. Adjunctive brexpiprazole for the treatment of major depressive disorder. Expert Opin Pharmacother. 2016 Dec;17(17):2331–9.
Beyer, John L., and Richard H. Weisler. “Adjunctive brexpiprazole for the treatment of major depressive disorder.Expert Opin Pharmacother, vol. 17, no. 17, Dec. 2016, pp. 2331–39. Pubmed, doi:10.1080/14656566.2016.1254188.
Beyer JL, Weisler RH. Adjunctive brexpiprazole for the treatment of major depressive disorder. Expert Opin Pharmacother. 2016 Dec;17(17):2331–2339.

Published In

Expert Opin Pharmacother

DOI

EISSN

1744-7666

Publication Date

December 2016

Volume

17

Issue

17

Start / End Page

2331 / 2339

Location

England

Related Subject Headings

  • Treatment Outcome
  • Thiophenes
  • Serotonin 5-HT1 Receptor Agonists
  • Receptors, Serotonin, 5-HT1
  • Receptors, Dopamine D2
  • Randomized Controlled Trials as Topic
  • Quinolones
  • Pharmacology & Pharmacy
  • Humans
  • Dopamine